-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Biopharmaceutical company Axesome Therapeutics has announced the start of a study on ACCORD, which evaluates the clinical efficacy of Alzheimer's disease, as a randomized, double-blind, placebo-controlled Phase III trial to assess the efficacy and safety of AXS-05 in treating Alzheimer's disease (AD) restlessness.
AXS-05 is a new, oral, research-based NMDA subjectant.
currently has no approved AD restlessness therapy.
results of the ACCORD test are expected to be released in the second half of 2022.
Alzheimer's disease is an aggressive neurodegenerative disease that is a common form of Alzheimer's disease characterized by cognitive decline and behavioral and psychological abnormalities, including restlessness.
addition to cognitive decline, up to 70 percent of Alzheimer's patients develop restlessness, characterized by depression, aggressive behavior, destructive irritability, and inhibition.
, the symptoms can accelerate cognitive decline and increase mortality.